171 related articles for article (PubMed ID: 35395077)
21. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
22. Construction of
Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
[TBL] [Abstract][Full Text] [Related]
23. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
[TBL] [Abstract][Full Text] [Related]
25. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
26. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
27. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
[TBL] [Abstract][Full Text] [Related]
28. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
29. Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes.
Mao C; Wang M; Li L; Tang JH
J Clin Lab Anal; 2022 Feb; 36(2):e24212. PubMed ID: 34994982
[TBL] [Abstract][Full Text] [Related]
30. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
31. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
[TBL] [Abstract][Full Text] [Related]
32. [Molecular Subtypes of Gastric Cancer].
Hatogai K; Doi T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):281-5. PubMed ID: 27067842
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
34. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
35. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
Braman N; Prasanna P; Whitney J; Singh S; Beig N; Etesami M; Bates DDB; Gallagher K; Bloch BN; Vulchi M; Turk P; Bera K; Abraham J; Sikov WM; Somlo G; Harris LN; Gilmore H; Plecha D; Varadan V; Madabhushi A
JAMA Netw Open; 2019 Apr; 2(4):e192561. PubMed ID: 31002322
[TBL] [Abstract][Full Text] [Related]
36. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
37. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
39. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
[TBL] [Abstract][Full Text] [Related]
40. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
